TWI450692B - Nutrient composition - Google Patents
Nutrient composition Download PDFInfo
- Publication number
- TWI450692B TWI450692B TW102109178A TW102109178A TWI450692B TW I450692 B TWI450692 B TW I450692B TW 102109178 A TW102109178 A TW 102109178A TW 102109178 A TW102109178 A TW 102109178A TW I450692 B TWI450692 B TW I450692B
- Authority
- TW
- Taiwan
- Prior art keywords
- nutritional composition
- per
- composition
- nutritional
- supplied
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 231
- 235000015097 nutrients Nutrition 0.000 title claims description 19
- 235000016709 nutrition Nutrition 0.000 claims description 190
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 39
- 150000003904 phospholipids Chemical class 0.000 claims description 35
- 229960001231 choline Drugs 0.000 claims description 30
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 30
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 27
- 150000002632 lipids Chemical class 0.000 claims description 26
- 150000001720 carbohydrates Chemical class 0.000 claims description 25
- 239000000787 lecithin Substances 0.000 claims description 24
- 235000010445 lecithin Nutrition 0.000 claims description 24
- 229940067606 lecithin Drugs 0.000 claims description 24
- 235000020958 biotin Nutrition 0.000 claims description 21
- 239000011616 biotin Substances 0.000 claims description 21
- 229960002685 biotin Drugs 0.000 claims description 21
- 108020004707 nucleic acids Proteins 0.000 claims description 20
- 102000039446 nucleic acids Human genes 0.000 claims description 20
- 150000007523 nucleic acids Chemical class 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 18
- 239000011669 selenium Substances 0.000 claims description 18
- 229910052711 selenium Inorganic materials 0.000 claims description 18
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 16
- 239000011701 zinc Substances 0.000 claims description 16
- 229910052725 zinc Inorganic materials 0.000 claims description 16
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 15
- 239000011651 chromium Substances 0.000 claims description 15
- 229910052804 chromium Inorganic materials 0.000 claims description 15
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 14
- 235000013824 polyphenols Nutrition 0.000 claims description 14
- 230000000813 microbial effect Effects 0.000 claims description 13
- 235000013325 dietary fiber Nutrition 0.000 claims description 12
- 239000004475 Arginine Substances 0.000 claims description 10
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 10
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 10
- 229930195729 fatty acid Natural products 0.000 claims description 10
- 239000000194 fatty acid Substances 0.000 claims description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 9
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 9
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 9
- 239000011575 calcium Substances 0.000 claims description 9
- 229910052791 calcium Inorganic materials 0.000 claims description 9
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 9
- 239000011777 magnesium Substances 0.000 claims description 9
- 229910052749 magnesium Inorganic materials 0.000 claims description 9
- 235000010755 mineral Nutrition 0.000 claims description 9
- 239000011573 trace mineral Substances 0.000 claims description 9
- 235000013619 trace mineral Nutrition 0.000 claims description 9
- 150000004665 fatty acids Chemical class 0.000 claims description 8
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 8
- 239000008158 vegetable oil Substances 0.000 claims description 8
- 150000001765 catechin Chemical class 0.000 claims description 7
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 7
- 235000005487 catechin Nutrition 0.000 claims description 7
- 235000021323 fish oil Nutrition 0.000 claims description 7
- 150000004667 medium chain fatty acids Chemical class 0.000 claims description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 7
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 6
- 229920001353 Dextrin Polymers 0.000 claims description 6
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- 239000011707 mineral Substances 0.000 claims description 6
- -1 biotin compound Chemical class 0.000 claims description 5
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 5
- 241000209140 Triticum Species 0.000 claims description 4
- 235000021307 Triticum Nutrition 0.000 claims description 4
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 4
- 235000019197 fats Nutrition 0.000 claims description 4
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 3
- 241000972773 Aulopiformes Species 0.000 claims description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 3
- 229920002770 condensed tannin Polymers 0.000 claims description 3
- 229960004488 linolenic acid Drugs 0.000 claims description 3
- 239000002366 mineral element Substances 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 235000019515 salmon Nutrition 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000000694 effects Effects 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 18
- 235000014633 carbohydrates Nutrition 0.000 description 17
- 238000012360 testing method Methods 0.000 description 16
- 241000700159 Rattus Species 0.000 description 15
- 239000002994 raw material Substances 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 235000009697 arginine Nutrition 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 235000003715 nutritional status Nutrition 0.000 description 7
- 208000019423 liver disease Diseases 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 102000004338 Transferrin Human genes 0.000 description 4
- 108090000901 Transferrin Proteins 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 150000002482 oligosaccharides Chemical class 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 239000012581 transferrin Substances 0.000 description 4
- PFRQBZFETXBLTP-RCIYGOBDSA-N 2-[(2e,6e,10e,14e,18e)-3,7,11,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaen-1-yl]-3-methyl-1,4-dihydronaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-RCIYGOBDSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 235000017060 Arachis glabrata Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 description 2
- 235000018262 Arachis monticola Nutrition 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 2
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 239000004495 emulsifiable concentrate Substances 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 229940030275 epigallocatechin gallate Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 235000021313 oleic acid Nutrition 0.000 description 2
- 235000020232 peanut Nutrition 0.000 description 2
- 239000011772 phylloquinone Substances 0.000 description 2
- MBWXNTAXLNYFJB-LKUDQCMESA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-LKUDQCMESA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229940083466 soybean lecithin Drugs 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 235000019710 soybean protein Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 description 2
- 229960005080 warfarin Drugs 0.000 description 2
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 244000007835 Cyamopsis tetragonoloba Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000008081 Intestinal Fistula Diseases 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920001991 Proanthocyanidin Polymers 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010039921 Selenium deficiency Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- RAKQPZMEYJZGPI-LJWNYQGCSA-N menaquinone-7 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 RAKQPZMEYJZGPI-LJWNYQGCSA-N 0.000 description 1
- 235000009464 menaquinone-7 Nutrition 0.000 description 1
- 239000011700 menaquinone-7 Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 208000037931 necrotizing enteritis Diseases 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940082569 selenite Drugs 0.000 description 1
- MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical compound [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 description 1
- 229940065287 selenium compound Drugs 0.000 description 1
- 150000003343 selenium compounds Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000002383 tung oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
本發明係關於一種具有優異營養效果之營養組成物。尤其係關於一種營養組成物，其對於消化道功能差的高齡者、需看護者，手術後初期、中期、後期之患者等需要長期投予輸液或經腸營養劑等的人而言，亦具有優異營養效果。The present invention relates to a nutritional composition having an excellent nutritional effect. In particular, it relates to a nutritional composition which is also useful for elderly people with poor digestive tract function, caregivers, patients who need long-term administration of infusion or enteral nutrition, etc. in patients in the early, middle, and late stages after surgery. Excellent nutritional effect.
以對於高齡者、需看護者，手術後初期、中期、後期之患者等難以攝取一般食物的人或早產兒等嬰幼兒之營養狀態的改善、維持為目的而開發多種營養組成物。A variety of nutritional compositions have been developed for the purpose of improving and maintaining the nutritional status of infants and young children such as elderly people, caregivers, and patients who are unable to take general foods, such as patients in the early, middle, and late stages of surgery.
例如，專利文獻1揭示一種營養組成物，其含有胞苷單磷酸(cytidine monophosphate；CMP)、尿苷單磷酸(uridine monophosphate；UMP)等核苷酸，含有一定量花生油酸、DHA及膽固醇之含有核酸關聯物質，並且記載該營養組成物具有增加脂質、蛋白質、膽固醇、核酸等之作用。For example, Patent Document 1 discloses a nutritional composition containing nucleotides such as cytidine monophosphate (CMP) and uridine monophosphate (UMP), and contains a certain amount of peanut oleic acid, DHA, and cholesterol. A nucleic acid-related substance, and it is described that the nutritional composition has an effect of increasing lipids, proteins, cholesterol, nucleic acids, and the like.
專利文獻2揭示一種營養組成物，其含有生育酚、磷脂醯乙醇胺、磷脂醯膽鹼及高脂肪酸，並且記載該營養組成物作為增強抗氧化力之營養組成物，可作成育兒用調製 乳、高齡者用食品、孕婦產婦哺乳婦用食品等。Patent Document 2 discloses a nutritional composition containing tocopherol, phospholipid, ethanolamine, phospholipid choline, and a high fatty acid, and the nutrient composition is described as a nutrient composition for enhancing antioxidant power, and can be prepared for childcare. Milk, food for the elderly, maternal breastfeeding women's food, etc.
又，專利文獻3記載一種減少產生嬰兒的壞死性全腸炎之方法，其係給予含有花生油酸、二十二碳六烯酸、卵磷脂質等之經腸營養組成物。Further, Patent Document 3 describes a method for reducing necrotizing enteritis in an infant by administering an enteral nutritional composition containing peanut oleic acid, docosahexaenoic acid, lecithin or the like.
本申請人亦開發一種有特定含有成分、重量比率、含量等之營養組成物，其係作為在對於無法攝取一般食物的患者，尤其係高齡者或需看護者之營養補給時所使用者(專利文獻4)。本發明者等進一步在本發明中試著提供一種具有優異營養效果之營養組成物。The present applicant has also developed a nutritional composition having a specific composition, a weight ratio, a content, and the like as a user for a nutritional supplement for a patient who cannot take general food, especially an elderly person or a caregiver (patent Document 4). The present inventors further tried to provide a nutritional composition having an excellent nutritional effect in the present invention.
[專利文獻1] 日本特許第3576318號[Patent Document 1] Japanese Patent No. 3576318
[專利文獻2] 日本特許第4073143號[Patent Document 2] Japanese Patent No. 4073143
[專利文獻3] 日本特表2001-516343號公報[Patent Document 3] Japanese Patent Publication No. 2001-516343
[專利文獻4] 日本特開2003-313142號公報[Patent Document 4] Japanese Patent Laid-Open Publication No. 2003-313142
本發明之課題係提供一種具有優異營養效果之營養組成物。本發明之課題尤其係提供一種營養組成物，其對於消化道功能差的高齡者、需看護者，手術後初期、中期、後期之患者等需要長期投予輸液或經腸營養劑等的人而言，亦具有優異營養效果。An object of the present invention is to provide a nutritional composition having an excellent nutritional effect. In particular, the subject of the present invention is to provide a nutritional composition for elderly people who have poor digestive tract function, caregivers, patients who are in the early, middle, and late stages after surgery, and those who need long-term administration of infusion or enteral nutrition. It also has excellent nutritional effects.
本發明者等為了解決上述課題而深入檢討之結果，發現滿足下述1)至10)之營養組成物成為具有優異營養效果之營養組成物，且對於需要長期投予輸液或經腸營養劑等的人而言，亦具有優異營養效果，而完成本發明。As a result of intensive review in order to solve the above problems, the present inventors have found that the nutritional composition satisfying the following 1) to 10) is a nutritional composition having an excellent nutritional effect, and it is necessary to inject an infusion or an enteral nutrient for a long period of time. For the sake of the person, it also has an excellent nutritional effect, and the present invention has been completed.
1)每100ml營養組成物之卡路里為90至120kcal。1) The calorie per 100 ml of the nutritional composition is 90 to 120 kcal.
2)每100ml營養組成物含有24至45mg膽鹼，該膽鹼係由磷脂質中含有60至90%磷脂醯膽鹼之卵磷脂來供給。2) Each 100 ml of the nutritional composition contains 24 to 45 mg of choline supplied from lecithin containing 60 to 90% of phospholipid choline in the phospholipid.
3)每100ml營養組成物含有4至6g蛋白質。3) 4 to 6 g of protein per 100 ml of the nutritional composition.
4)每100ml營養組成物含有2.20至3.36g脂質，作為該脂質而含有魚油、植物油、中鏈脂肪酸三甘油酯或脂肪酸單甘油酯之任一種以上。4) The lipid composition contains 2.20 to 3.36 g of a lipid per 100 ml of the nutrient composition, and contains at least one of fish oil, vegetable oil, medium chain fatty acid triglyceride or fatty acid monoglyceride as the lipid.
5)每100ml營養組成物含有10.5至16.1g碳水化合物，作為該碳水化合物而含有糊精及水溶性食物纖維。5) Each 100 ml of the nutritional composition contains 10.5 to 16.1 g of a carbohydrate, and as the carbohydrate, it contains dextrin and water-soluble dietary fiber.
6)每100ml營養組成物含有15至330mg多酚類。6) 15 to 330 mg of polyphenols per 100 ml of the nutritional composition.
7)每100ml營養組成物含有3.3至6.3μg/100ml生物素。7) 3.3 to 6.3 μg / 100 ml of biotin per 100 ml of the nutritional composition.
8)每100ml營養組成物含有50至76mg鈣、24至38mg鎂、1.5至10μg硒及1.20至1.65mg鋅、4至9μg鉻作為礦物質/微量元素。8) Each 100 ml of the nutritional composition contains 50 to 76 mg of calcium, 24 to 38 mg of magnesium, 1.5 to 10 g of selenium, and 1.20 to 1.65 mg of zinc, and 4 to 9 g of chromium as minerals/trace elements.
9)每100ml營養組成物含有0.4至0.5g精胺酸及0.6至0.9g麩醯胺。9) 0.4 to 0.5 g of arginine and 0.6 to 0.9 g of branamine per 100 ml of the nutritional composition.
10)每100ml營養組成物含有5至20mg核酸。10) 5 to 20 mg of nucleic acid per 100 ml of the nutritional composition.
亦即，本發明係關於下述(1)至(9)之營養組成物等。That is, the present invention relates to the nutritional composition and the like of the following (1) to (9).
(1)一種營養組成物，其係含有：膽鹼、蛋白質、脂質、碳水化合物、水溶性食物纖維、多酚類、生物素、礦物質/微量元素、精胺酸、麩醯胺及核酸，且該營養組成物係滿足下述1)至10)者。(1) A nutritional composition comprising: choline, protein, lipid, carbohydrate, water-soluble dietary fiber, polyphenols, biotin, minerals/trace elements, arginine, glutamine, and nucleic acid, And the nutritional composition meets the following 1) to 10).
1)每100ml營養組成物之卡路里為90至120kcal。1) The calorie per 100 ml of the nutritional composition is 90 to 120 kcal.
2)每100ml營養組成物含有24至45mg膽鹼，該膽鹼係由磷脂質中含有60至90%磷脂醯膽鹼之卵磷脂來供給。2) Each 100 ml of the nutritional composition contains 24 to 45 mg of choline supplied from lecithin containing 60 to 90% of phospholipid choline in the phospholipid.
3)每100ml營養組成物含有4至6g蛋白質。3) 4 to 6 g of protein per 100 ml of the nutritional composition.
4)每100ml營養組成物含有2.20至3.36g脂質，作為該脂質而含有魚油、植物油、中鏈脂肪酸三甘油酯或脂肪酸單甘油酯之任一種以上。4) The lipid composition contains 2.20 to 3.36 g of a lipid per 100 ml of the nutrient composition, and contains at least one of fish oil, vegetable oil, medium chain fatty acid triglyceride or fatty acid monoglyceride as the lipid.
5)每100ml營養組成物含有10.5至16.1g碳水化合物，作為該碳水化合物而含有糊精及水溶性食物纖維。5) Each 100 ml of the nutritional composition contains 10.5 to 16.1 g of a carbohydrate, and as the carbohydrate, it contains dextrin and water-soluble dietary fiber.
6)每100ml營養組成物含有15至330mg多酚類。6) 15 to 330 mg of polyphenols per 100 ml of the nutritional composition.
7)每100ml營養組成物含有3.3至6.3μg生物素。7) 3.3 to 6.3 μg of biotin per 100 ml of the nutritional composition.
8)每100ml營養組成物含有50至76mg鈣、24至38mg鎂、1.5至10μg硒及1.20至1.65mg鋅、4至9μg鉻作為礦物質/微量元素。8) Each 100 ml of the nutritional composition contains 50 to 76 mg of calcium, 24 to 38 mg of magnesium, 1.5 to 10 g of selenium, and 1.20 to 1.65 mg of zinc, and 4 to 9 g of chromium as minerals/trace elements.
9)每100ml營養組成物含有0.4至0.5g精胺酸及0.6至0.9g麩醯胺。9) 0.4 to 0.5 g of arginine and 0.6 to 0.9 g of branamine per 100 ml of the nutritional composition.
10)每100ml營養組成物含有5至20mg核酸。10) 5 to 20 mg of nucleic acid per 100 ml of the nutritional composition.
(2)上述(1)所述之營養組成物，其中，脂質係如下之構成：每100ml營養組成物中含有0.8至1.2g中鏈脂肪酸甘油酯、0.16至0.42g亞麻油酸、0.08至0.18g α-次亞麻油酸、 14至40mg二十碳五烯酸、9至30mg二十二碳六烯酸。(2) The nutritional composition according to the above (1), wherein the lipid is composed of 0.8 to 1.2 g of a medium chain fatty acid glyceride, 0.16 to 0.42 g of linoleic acid, 0.08 to 0.18 per 100 ml of the nutritional composition. g α-linolenic acid, 14 to 40 mg of eicosapentaenoic acid and 9 to 30 mg of docosahexaenoic acid.
(3)上述(1)或(2)所述之營養組成物，其中，碳水化合物係每100ml營養組成物含有0.4至1.8g水溶性食物纖維之碳水化合物。(3) The nutritional composition according to the above (1) or (2), wherein the carbohydrate contains 0.4 to 1.8 g of carbohydrate of the water-soluble dietary fiber per 100 ml of the nutritional composition.
(4)上述(1)至(3)之任一項所述之營養組成物，其中，多酚類係由兒茶素類、原花青素(proanthocyanidin)來供給。(4) The nutritional composition according to any one of (1) to (3) above, wherein the polyphenols are supplied from catechins and proanthocyanidin.
(5)上述(1)至(4)之任一項所述之營養組成物，其中，生物素係由生物素化合物或含有生物素之微生物菌體來供給。(5) The nutritional composition according to any one of (1) to (4) wherein the biotin is supplied from a biotin compound or a biotin-containing microbial cell.
(6)上述(1)至(5)之任一項所述之營養組成物，其中，鋅係由含有鋅之微生物菌體來供給，硒係由含有硒之微生物菌體來供給，鉻係由含有鉻之微生物菌體來供給。(6) The nutrient composition according to any one of the above aspects, wherein the zinc is supplied from a microbial cell containing zinc, and the selenium is supplied from a microbial cell containing selenium. It is supplied from a microbial cell containing chromium.
(7)上述(1)至(6)之任一項所述之營養組成物，其中，麩醯胺係由小麥胜肽來供給。(7) The nutritional composition according to any one of (1) to (6) wherein the branamide is supplied from a wheat peptide.
(8)上述(1)至(7)之任一項所述之營養組成物，其中，核酸係由鮭魚精核酸來供給。(8) The nutritional composition according to any one of (1) to (7) wherein the nucleic acid is supplied from salmon sperm nucleic acid.
(9)上述(1)至(8)之任一項所述之營養組成物，其係高齡者用營養組成物。(9) The nutritional composition according to any one of (1) to (8) above which is a nutritional composition for elderly people.
本發明之營養組成物藉由調配磷脂質中之磷脂醯膽鹼含量提高之卵磷脂，可提供乳化安定性高、呈味性優異者。The nutritional composition of the present invention can provide a high emulsion stability and an excellent taste property by blending lecithin having an increased phospholipid choline content in a phospholipid.
藉由提供本發明之營養組成物，攝取或投予的人之營養狀態的維持、改善變容易。藉由本發明之營養組成物，消化道功能差、營養狀態易惡化之高齡者等之營養狀態的 維持、改善亦變容易。又，本發明之營養組成物，係有對於便臭之改善亦有效、肝臟疾病之抑制效果高之優點。By providing the nutritional composition of the present invention, it is easy to maintain and improve the nutritional status of a person who is ingested or administered. By the nutritional composition of the present invention, the nutritional status of an elderly person having poor digestive tract function and prone to deterioration of nutritional status It is also easier to maintain and improve. Further, the nutritional composition of the present invention is advantageous in that it is effective for improving the odor and has a high inhibitory effect on liver diseases.
第1圖係表示將本發明之營養組成物、對照組成物投予至大鼠時之體重測定結果之圖(試驗例2)。Fig. 1 is a graph showing the results of measurement of body weight when the nutritional composition and the control composition of the present invention were administered to a rat (Test Example 2).
第2圖係表示將本發明之營養組成物(組成物A、組成物B)、對照組成物(組成物a、組成物b)投予至大鼠時之下述營養指標之測定結果之圖。Fig. 2 is a view showing the measurement results of the following nutritional indicators when the nutritional composition (composition A, composition B) and the control composition (composition a, composition b) of the present invention are administered to a rat. .
營養指標：A.血清中之白蛋白濃度、B.血清中之總蛋白質濃度、C.血清中之運鐵蛋白濃度Nutritional indicators: A. albumin concentration in serum, B. total protein concentration in serum, C. transferrin concentration in serum
本發明之「營養組成物」係指以營養狀態的改善、維持為目的而攝取或投予並滿足下述1)至10)之營養組成物。The "nutritional composition" of the present invention refers to a nutritional composition which is ingested or administered for the purpose of improving and maintaining the nutritional state and satisfying the following 1) to 10).
1)每100ml營養組成物之卡路里為90至120kcal。1) The calorie per 100 ml of the nutritional composition is 90 to 120 kcal.
2)每100ml營養組成物含有24至45mg膽鹼，該膽鹼係由磷脂質中含有60至90%磷脂醯膽鹼之卵磷脂來供給。2) Each 100 ml of the nutritional composition contains 24 to 45 mg of choline supplied from lecithin containing 60 to 90% of phospholipid choline in the phospholipid.
3)每100ml營養組成物含有4至6g蛋白質。3) 4 to 6 g of protein per 100 ml of the nutritional composition.
4)每100ml營養組成物含有2.20至3.36g脂質，作為該脂質而含有魚油、植物油、中鏈脂肪酸三甘油酯或脂肪酸單甘油酯之任一種以上。4) The lipid composition contains 2.20 to 3.36 g of a lipid per 100 ml of the nutrient composition, and contains at least one of fish oil, vegetable oil, medium chain fatty acid triglyceride or fatty acid monoglyceride as the lipid.
5)每100ml營養組成物含有10.5至16.1g碳水化合物，作為該碳水化合物而含有糊精及水溶性食物纖維。5) Each 100 ml of the nutritional composition contains 10.5 to 16.1 g of a carbohydrate, and as the carbohydrate, it contains dextrin and water-soluble dietary fiber.
6)每100ml營養組成物含有15至330mg多酚類。6) 15 to 330 mg of polyphenols per 100 ml of the nutritional composition.
7)每100ml營養組成物含有3.3至6.3μg/100mg生物素。7) 3.3 to 6.3 μg / 100 mg biotin per 100 ml of the nutritional composition.
8)每100ml營養組成物含有50至76mg鈣、24至38mg鎂、1.5至10μg硒及1.20至1.65mg鋅、4至9μg鉻作為礦物質/微量元素。8) Each 100 ml of the nutritional composition contains 50 to 76 mg of calcium, 24 to 38 mg of magnesium, 1.5 to 10 g of selenium, and 1.20 to 1.65 mg of zinc, and 4 to 9 g of chromium as minerals/trace elements.
9)每100ml營養組成物含有0.4至0.5g精胺酸及0.6至0.9g麩醯胺。9) 0.4 to 0.5 g of arginine and 0.6 to 0.9 g of branamine per 100 ml of the nutritional composition.
10)每100ml營養組成物含有5至20mg核酸。10) 5 to 20 mg of nucleic acid per 100 ml of the nutritional composition.
此種本發明之「營養組成物」係可以需要營養之任何動物作為攝取或投予對象，尤其係以消化道功能差的高齡者、需看護者，手術後初期、中期、後期之患者等需要長期投予輸液或經腸營養劑等的人，或者早產兒等嬰幼兒作為對象之營養組成物。又，不僅可經口攝取，亦可作為流動食等藉由鼻腔管等經管、或者胃廔管或腸廔管等經腸而投予。The "nutritional composition" of the present invention is any animal that needs nutrition as an ingesting or administering object, in particular, an elderly person with a poor digestive tract function, a caregiver, a patient in the early, middle, and late stages after surgery. Long-term administration of infusion or enteral nutrition, etc., or infants and young children such as premature infants as a nutritional component. Further, it can be administered not only by mouth, but also as a liquid food or the like by a nasal tube or the like, or a gastrostomy tube or an intestinal fistula.
此種本發明之「營養組成物」係依攝取的人的年齡或症狀等而異，但較佳係以成人每人一天成為800kcal至2500kcal之方式攝取或投予。The "nutritional composition" of the present invention varies depending on the age, symptoms, and the like of the person to be ingested, but is preferably taken or administered in such a manner that the adult becomes 800 kcal to 2500 kcal per day.
本發明之「營養組成物」中之「膽鹼」只要每100ml營養組成物含有24至45mg即可，較佳係含有26至37mg，更佳係含有28至30mg。The "choline" in the "nutritional composition" of the present invention may be contained in an amount of 24 to 45 mg per 100 ml of the nutritional composition, preferably 26 to 37 mg, more preferably 28 to 30 mg.
「膽鹼」係由將磷脂質中含有60至90%磷脂醯膽鹼之卵磷脂作為原料來供給者。磷脂醯膽鹼與氯化膽鹼等相比，有可維持高的血液中之膽鹼濃度之優點。The "choline" is supplied by using lecithin which contains 60 to 90% of phospholipid choline in the phospholipid as a raw material. Phospholipid choline has the advantage of maintaining a high concentration of choline in the blood compared to choline chloride and the like.
磷脂質中含有60至90%磷脂醯膽鹼之卵磷脂只要係可使用作為營養組成物之原料者，即可為以往已知之任何卵磷脂。就此種卵磷脂而言，可舉例如使大豆卵磷脂中特定的磷脂質濃度改變之分級(fractionation)卵磷脂。例如，分級卵磷脂中，較佳係磷脂質中含有60至90%磷脂醯膽鹼之大豆卵磷脂，更佳係磷脂質中含有70至90%磷脂醯膽鹼之高純度大豆卵磷脂。藉由調配高純度大豆卵磷脂可易提供顯現乳化安定性高且呈味性優異之本發明之營養組成物。本發明之營養組成物中可包含含有70%磷脂醯膽鹼之SLP-PC70(辻製油股份有限公司)等市售品作為此種卵磷脂。The lecithin containing 60 to 90% of phospholipid choline in the phospholipid may be any lecithin known in the art as long as it can be used as a raw material of the nutritional composition. As such a lecithin, for example, a fractionation lecithin which changes a specific phospholipid concentration in soybean lecithin can be mentioned. For example, in the fractionated lecithin, it is preferred that the phospholipid contains 60 to 90% of phospholipid choline soy lecithin, and more preferably the phospholipid contains 70 to 90% of phospholipid choline high-purity soy lecithin. By formulating the high-purity soybean lecithin, it is easy to provide the nutritional composition of the present invention which exhibits high emulsion stability and excellent taste. The nutritional composition of the present invention may contain, as such a lecithin, a commercial product such as SLP-PC70 (Mulberry Oil Co., Ltd.) containing 70% of phospholipid choline.
本發明之「營養組成物」中之「蛋白質」只要每100ml營養組成物含有4至6g即可，較佳係含有4.5至5.5g。The "protein" in the "nutritional composition" of the present invention may be contained in an amount of 4 to 6 g per 100 ml of the nutritional composition, and preferably 4.5 to 5.5 g.
「蛋白質」只要係營養組成物可含有之蛋白質，即可為以往已知之任何蛋白質，可舉例如乳蛋白質、卵蛋白質、小麥蛋白質、濃縮大豆蛋白質等大豆蛋白質。又，亦可為該等之分解物、或胺基酸混合物。本發明之營養組成物中可含有市售品作為該等蛋白質。The "protein" is any protein known in the art as long as it is a protein which can be contained in the nutritional composition, and examples thereof include soybean protein such as milk protein, egg protein, wheat protein, and concentrated soybean protein. Further, it may be such a decomposition product or an amino acid mixture. The nutritional composition of the present invention may contain a commercially available product as the protein.
本發明之「營養組成物」中之「脂質」只要每100ml營養組成物含有2.20至3.36g即可，較佳係含有2.5至3.0g。The "lipid" in the "nutritional composition" of the present invention may be contained in an amount of 2.20 to 3.36 g per 100 ml of the nutritional composition, preferably 2.5 to 3.0 g.
「脂質」只要係營養組成物可含有之脂質，即可為以往已知之任何脂質，可舉例如魚油、植物油、中鏈脂肪酸 三甘油酯或脂肪酸單甘油酯等。必須含有該等魚油、植物油、中鏈脂肪酸三甘油酯或脂肪酸單甘油酯之至少一種以上，特佳係全部含有。再者，就植物油而言，可舉例如紫蘇油、荏胡麻油、亞麻仁油、桐油、紅花子油、玉米油、大豆油、菜籽油等。本發明之營養組成物中可含有一種以上市售品作為該等脂質。The "lipid" is any lipid known in the art as long as it is a lipid which can be contained in the nutritional composition, and examples thereof include fish oil, vegetable oil, and medium chain fatty acid. Triglyceride or fatty acid monoglyceride. It is necessary to contain at least one or more of such fish oil, vegetable oil, medium chain fatty acid triglyceride or fatty acid monoglyceride, and all of them are contained in all. Further, as the vegetable oil, for example, perilla oil, eucalyptus oil, linseed oil, tung oil, safflower oil, corn oil, soybean oil, rapeseed oil, and the like can be mentioned. The nutritional composition of the present invention may contain a marketed product as the lipid.
本發明之「營養組成物」中之「脂質」特佳係如下之構成：每100ml營養組成物中含有0.8g至1.2g中鏈脂肪酸甘油酯、0.16至0.42g亞麻油酸、0.08至0.18g α-次亞麻油酸、14至40mg二十碳五烯酸、9至30mg二十二碳六烯酸。The "lipid" in the "nutritional composition" of the present invention is particularly preferably composed of 0.8 g to 1.2 g of a medium chain fatty acid glyceride, 0.16 to 0.42 g of linoleic acid, and 0.08 to 0.18 g per 100 ml of the nutritional composition. Alpha-linolenic acid, 14 to 40 mg eicosapentaenoic acid, 9 to 30 mg docosahexaenoic acid.
本發明之「營養組成物」中之「碳水化合物」只要每100ml營養組成物含有10.5至16.1g即可，較佳係含有13.0至15.5g。再者，本發明之「營養組成物」中之「碳水化合物」特佳係含有「糖質」，同時每100ml營養組成物含有0.4至1.8g水溶性食物纖維之碳水化合物。The "carbohydrate" in the "nutritional composition" of the present invention may be contained in an amount of 10.5 to 16.1 g per 100 ml of the nutritional composition, preferably 13.0 to 15.5 g. Further, the "carbohydrate" in the "nutritional composition" of the present invention contains "glyco", and contains 0.4 to 1.8 g of carbohydrate of water-soluble dietary fiber per 100 ml of the nutritional composition.
「碳水化合物」所含之「糖質」只要係營養組成物可含有之糖質，即可為以往已知之任何糖質，可舉例如澱粉、蔗糖、糊精、寡糖、葡萄糖、麥芽糖等。其中，就寡糖而言，可舉例如果寡糖、大豆寡糖、半乳寡糖、木寡糖等。又，就水溶性食物纖維而言，可含有源自果實/蔬菜之水溶性果膠、源自蒟蒻/日本樹薯之聚葡甘露糖(glucomannan)、源自燕麥/豆類之聚半乳甘露糖，源自瓊脂、海帶/裙帶菜等海藻類之海藻酸，源自紅藻類之卡拉膠、瓜爾膠酵素分 解物等。該等糖質、水溶性食物纖維，可使用市售品。The "saccharin" contained in the "carbohydrate" may be any saccharide known in the art as long as it is a saccharide which may be contained in the nutrient composition, and examples thereof include starch, sucrose, dextrin, oligosaccharide, glucose, maltose and the like. Among them, in the case of oligosaccharides, oligosaccharides, soybean oligosaccharides, galactooligosaccharides, xylooligosaccharides and the like can be exemplified. Further, in the case of the water-soluble dietary fiber, it may contain water-soluble pectin derived from fruit/vegetable, glucomannan derived from 蒟蒻/Japanese cassava, and polygalactomannose derived from oat/bean Alginic acid derived from seaweed such as agar, kelp/waka, and carrageenan and guar enzyme derived from red algae Dissolve and so on. Commercially available products can be used as the saccharide or water-soluble dietary fiber.
本發明之「營養組成物」中之「多酚類」只要每100ml營養組成物含有15至330mg即可，較佳係含有30至60mg。The "polyphenols" in the "nutritional composition" of the present invention may be contained in an amount of 15 to 330 mg per 100 ml of the nutritional composition, preferably 30 to 60 mg.
「多酚類」只要係營養組成物可含有之多酚類，即可為以往已知之任何多酚類，可舉例如兒茶素類、原花青素等。兒茶素類之來源及型態無特別限定，較佳係源自綠茶、烏龍茶、紅茶等茶之兒茶素，更佳係含有10至70重量%表沒食子兒茶素沒食子酸酯(epigallocatechin gallate)之兒茶素類。又，可舉例如兒茶素的聚合物之單寧、或源自葡萄種子之原花青素等。本發明之營養組成物中可含有市售品作為該等多酚類。The "polyphenols" are any polyphenols known in the art as long as they are polyphenols, and examples thereof include catechins and proanthocyanidins. The source and type of catechins are not particularly limited, and are preferably derived from tea catechins such as green tea, oolong tea, and black tea, and more preferably from 10 to 70% by weight of epigallocatechin gallate. The catechins of the ester (epigallocatechin gallate). Further, for example, tannins of polymers of catechins, or proanthocyanidins derived from grape seeds, and the like can be mentioned. A commercially available product may be contained in the nutritional composition of the present invention as the polyphenols.
本發明之「營養組成物」中之「生物素」只要每100ml營養組成物含有3.3至6.3μg即可，較佳係含有3.5至5.2μg。The "biotin" in the "nutritional composition" of the present invention may be contained in an amount of 3.3 to 6.3 μg per 100 ml of the nutritional composition, and preferably 3.5 to 5.2 μg.
「生物素」只要係營養組成物可含有之生物素，即可為以往已知之任何生物素，較佳係以生物素化合物、含有生物素之微生物菌體等作為原料所供給者。本發明之營養組成物中可含有市售品作為該等生物素或含有生物素之原料。The "biotin" is any biotin which is known in the art as long as it is a biotin which can be contained in the nutritional composition, and is preferably a biotin compound or a biomicrobial microbial cell or the like as a raw material. The nutritional composition of the present invention may contain a commercially available product as the biotin or a biotin-containing raw material.
再者，就生物素以外之維生素類而言，可含有維生素A、維生素D、維生素E、維生素B1 、維生素B2 、維生素B6 、維生素B12 、維生素C、維生素K1 、維生素K2 、菸鹼、泛酸、葉酸等或者該等之混合物。Furthermore, vitamins other than biotin may contain vitamin A, vitamin D, vitamin E, vitamin B 1 , vitamin B 2 , vitamin B 6 , vitamin B 12 , vitamin C, vitamin K 1 , and vitamin K 2 . , nicotine, pantothenic acid, folic acid, etc. or a mixture of such.
其中，雖然以往以來作為營養組成物的成分而調配有維生素K1 ，但由於已知會減弱為了預防血栓性栓塞症而對高齡者、需看護者處方之殺鼠靈(warfarin)的作用，較佳係含有減弱作用弱之維生素K2 。此時，較佳係調配源自納豆菌等之甲萘醌-7(menaquinone-7)作為維生素K2 ，較佳係以每100ml營養組成物含有4至16μg之方式調配。此係由於超過16μg時，會產生引發減弱殺鼠靈的作用等副作用之可能性，未達4μg時，會產生血栓性栓塞症的預防效果減弱之可能性。Among them, although vitamin K 1 has been conventionally formulated as a component of a nutritional composition, it is known that it is preferable to reduce the effect of warfarin prescribed for elderly people and caregivers in order to prevent thrombotic embolism. It contains vitamin K 2 with weak attenuating effect. In this case, it is preferred to formulate menaquinone-7 derived from natto or the like as vitamin K 2 , preferably in such a manner that it contains 4 to 16 μg per 100 ml of the nutritional composition. When it exceeds 16 μg, there is a possibility that side effects such as attenuating the action of warfarin are caused, and when it is less than 4 μg, the prevention effect of thrombotic embolism may be weakened.
作為本發明之「營養組成物」中之「礦物質/微量元素」，只要每100ml營養組成物含有50至76mg鈣、24至38mg鎂、1.5至10μg硒及1.20至1.65mg鋅、4至9μg鉻即可，較佳係含有54至65mg鈣、27至35mg鎂、4至6μg硒及1.3至1.6mg鋅、5至8μg鉻。此外，作為「礦物質/微量元素」，可含有鈉、鉀、磷、氯、鐵、銅、錳、碘等之有機鹽或無機鹽。As the "mineral/trace element" in the "nutritional composition" of the present invention, it is only required to contain 50 to 76 mg of calcium, 24 to 38 mg of magnesium, 1.5 to 10 g of selenium, and 1.20 to 1.65 mg of zinc, 4 to 9 μg per 100 ml of the nutritional composition. Chromium is preferred, preferably containing 54 to 65 mg of calcium, 27 to 35 mg of magnesium, 4 to 6 g of selenium, and 1.3 to 1.6 mg of zinc, and 5 to 8 g of chromium. Further, as the "mineral/trace element", an organic salt or an inorganic salt such as sodium, potassium, phosphorus, chlorine, iron, copper, manganese or iodine may be contained.
「鈣」、「鎂」、「硒」、「鋅」、「鉻」只要係營養組成物可含有者，即可為以往已知之任意者。"Calcium", "magnesium", "selenium", "zinc", and "chromium" may be any of the conventionally known ones as long as they are contained in the nutritional composition.
其中，「硒」可為有機或無機型態之任一種，亦可為以在含有亞硒酸鹽、硒胺基酸、高濃度硒化合物之培養基內培養所獲得之含有硒之微生物菌體等作為原料所供給者。特佳係以含有硒之微生物菌體等作為原料所供給者。再者，就本發明之營養組成物中之硒的含量而言，若超過10μg則會產生安全性之問題，未達1.5μg時會有陷入硒缺 乏症之可能性。The "selenium" may be either an organic or inorganic type, or may be a microbial cell containing selenium obtained by culturing in a medium containing selenite, selenoamine, or a high concentration of selenium compound. As a supplier of raw materials. It is a supplier of microbial cells containing selenium as a raw material. Furthermore, in the case of the content of selenium in the nutritional composition of the present invention, if it exceeds 10 μg, there is a problem of safety, and if it is less than 1.5 μg, it will be trapped in selenium deficiency. The possibility of lack of disease.
「鋅」較佳係由含有鋅之微生物菌體等作為原料所供給者，「鉻」較佳係由含有鉻之微生物菌體等作為原料所供給者。"Zinc" is preferably supplied as a raw material from a microbial cell containing zinc or the like, and "chromium" is preferably supplied as a raw material from a microbial cell containing chromium.
本發明之營養組成物中可含有市售品作為「鈣」、「鎂」、「硒」或含有硒之原料、「鋅」或含有鋅之原料、「鉻」或含有鉻之原料。The nutritional composition of the present invention may contain a commercially available product as "calcium", "magnesium", "selenium" or a raw material containing selenium, "zinc" or a raw material containing zinc, "chromium" or a raw material containing chromium.
本發明之「營養組成物」中之「精胺酸」只要每100ml營養組成物含有0.4至0.5g即可，「麩醯胺」只要每100ml營養組成物含有0.6至0.9g即可。The "arginine" in the "nutrition composition" of the present invention may be contained in an amount of 0.4 to 0.5 g per 100 ml of the nutritional composition, and the "glutaramine" may be contained in an amount of 0.6 to 0.9 g per 100 ml of the nutritional composition.
該等只要係營養組成物可含有者，即可為以往已知之任意者，就精胺酸而言，例如可含有「L-精胺酸」。麩醯胺特佳係以「小麥胜肽」等作為原料所供給者。藉此，可調製營養組成物之胺基酸組成中之麩醯胺含量。本發明之營養組成物中可含有市售品作為該等精胺酸、麩醯胺或含有麩醯胺之原料。These may be any conventionally known as long as the nutritional composition is contained, and for example, arginine may contain "L-arginine". The branamine is best supplied as a raw material such as "wheat peptide". Thereby, the content of the branamine in the amino acid composition of the nutritional composition can be adjusted. The nutritional composition of the present invention may contain a commercially available product as the raw material of the arginine, branamine or branamine.
本發明之「營養組成物」中之「核酸」只要每100ml營養組成物含有5至20mg即可，較佳係含有10至15mg。The "nucleic acid" in the "nutritional composition" of the present invention may be contained in an amount of 5 to 20 mg per 100 ml of the nutritional composition, preferably 10 to 15 mg.
「核酸」只要係營養組成物可含有之核酸，即可為以往已知之任何核酸，較佳係以鮭魚精核酸等作為原料所供給者。本發明之營養組成物中可含有市售品作為該等核酸或含有核酸之原料。The "nucleic acid" is any nucleic acid known in the art as long as it is a nucleic acid which can be contained in the nutritional composition, and is preferably supplied as a raw material using salmon sperm nucleic acid or the like. The nutritional composition of the present invention may contain a commercially available product as the nucleic acid or a nucleic acid-containing material.
再者，本發明之「營養組成物」除了上述 成分以外，尚可因應需要而含有其他成分或藥學上容許之載體等。Furthermore, the "nutritional composition" of the present invention is in addition to the above In addition to the ingredients, other ingredients or pharmaceutically acceptable carriers may be included as needed.
本發明之「營養組成物」之型態無特別限定，可舉例如將各成分粉碎混合所得之粉末狀營養組成物，或溶解於水等溶劑中之液狀營養組成物，進一步將其乾燥所得之粉末狀營養組成物等。液狀營養組成物在調製時，可因應需要而含有脂肪酸甘油酯、蔗糖脂肪酸酯等乳化劑等。The form of the "nutritional composition" of the present invention is not particularly limited, and examples thereof include a powdery nutritional composition obtained by pulverizing and mixing the respective components, or a liquid nutritional composition dissolved in a solvent such as water, and further dried. A powdery nutritional composition or the like. When preparing the liquid nutritional composition, an emulsifier such as a fatty acid glyceride or a sucrose fatty acid ester may be contained as needed.
以下，列舉實施例、試驗例更詳細說明本發明，但本發明不限於該等實施例、試驗例。Hereinafter, the present invention will be described in more detail by way of examples and test examples, but the invention is not limited to the examples and the examples.
以表1所示之組成，依照一般方法調製營養組成物。又，磷脂質中調配有37.5%磷脂醯膽鹼之分級卵磷脂，並以同樣方式調製對照組成物。針對該營養組成物及對照組成物，將每100ml(100kcal)之蛋白質、碳水化合物、脂質等之淨含量示於表2。The nutrient composition was prepared in accordance with a general method in the composition shown in Table 1. Further, a phospholipid was formulated with a fractionated lecithin of 37.5% phospholipid choline, and a control composition was prepared in the same manner. The net content of protein, carbohydrate, lipid, etc. per 100 ml (100 kcal) is shown in Table 2 for the nutritional composition and the control composition.
營養組成物係滿足下述1)至10)之營養組成物。The nutritional composition is a nutritional composition satisfying the following 1) to 10).
1)每100ml營養組成物之卡路里為90至120kcal。1) The calorie per 100 ml of the nutritional composition is 90 to 120 kcal.
2)每100ml營養組成物含有24至45mg膽鹼，該膽鹼係由磷脂質中含有60至90%磷脂醯膽鹼之卵磷脂來供給。2) Each 100 ml of the nutritional composition contains 24 to 45 mg of choline supplied from lecithin containing 60 to 90% of phospholipid choline in the phospholipid.
3)每100ml營養組成物含有4至6g蛋白質。3) 4 to 6 g of protein per 100 ml of the nutritional composition.
4)每100ml營養組成物含有2.20至3.36g脂質，作為該脂質而含有魚油、植物油、中鏈脂肪酸三甘油酯或脂肪酸單 甘油酯之任一種以上。4) Containing 2.20 to 3.36 g of lipid per 100 ml of the nutritional composition, containing fish oil, vegetable oil, medium chain fatty acid triglyceride or fatty acid single as the lipid Any one or more of glycerides.
5)每100ml營養組成物含有10.5至16.1g碳水化合物，作為該碳水化合物而含有糊精及水溶性食物纖維。5) Each 100 ml of the nutritional composition contains 10.5 to 16.1 g of a carbohydrate, and as the carbohydrate, it contains dextrin and water-soluble dietary fiber.
6)每100ml營養組成物含有15至330mg多酚類。6) 15 to 330 mg of polyphenols per 100 ml of the nutritional composition.
7)每100ml營養組成物含有3.3至6.3μg/100mg生物素。7) 3.3 to 6.3 μg / 100 mg biotin per 100 ml of the nutritional composition.
8)每100ml營養組成物含有50至76mg鈣、24至38mg鎂、1.5至10μg硒及1.20至1.65mg鋅、4至9μg鉻作為礦物質/微量元素。8) Each 100 ml of the nutritional composition contains 50 to 76 mg of calcium, 24 to 38 mg of magnesium, 1.5 to 10 g of selenium, and 1.20 to 1.65 mg of zinc, and 4 to 9 g of chromium as minerals/trace elements.
9)每100ml營養組成物含有0.4至0.5g精胺酸及0.60至0.90g麩醯胺。9) 0.4 to 0.5 g of arginine and 0.60 to 0.90 g of branamine per 100 ml of the nutritional composition.
10)每100ml營養組成物含有5至20mg核酸。10) 5 to 20 mg of nucleic acid per 100 ml of the nutritional composition.
針對上述實施例1之營養組成物與對照組成物，分別評估初期物性、乳油分離(creaming)、呈味性。The nutrient composition and the control composition of the above Example 1 were evaluated for initial physical properties, creaming, and taste properties, respectively.
將營養組成物與對照組成物於常溫靜置24小時後，測定各組成物之粒徑中值(median diameter有稱為中值粒徑的情形)、pH、黏度。After the nutrient composition and the control composition were allowed to stand at room temperature for 24 hours, the median diameter of each of the compositions (the median diameter is referred to as a median diameter), pH, and viscosity were measured.
粒徑中值之測定係使用Laser Scattering Particle Size Distribution LA920(HORIBA)，pH之測定係使用pH/Ion Meter F-53(HORIBA)，黏度之測定係使用Vismetron VDA(B型黏度計)(SHIBAURA SYSTEMS ℃O.LTD)。The median particle size was measured using Laser Scattering Particle Size Distribution LA920 (HORIBA), the pH was measured using pH/Ion Meter F-53 (HORIBA), and the viscosity was measured using Vismetron VDA (B type viscometer) (SHIBAURA SYSTEMS) °CO.LTD).
其結果如表3所示，可確認相對於含有卵磷脂(2)(即分級卵磷脂)的對照組成物之粒徑中值為0.507μm，含有卵磷脂(1)(即含有高含量磷脂醯膽鹼之卵磷脂)的營養組成物之粒徑中值為0.3μm，有大幅減少之情形。As a result, as shown in Table 3, it was confirmed that the median diameter of the control composition containing lecithin (2) (i.e., fractionated lecithin) was 0.507 μm, and lecithin (1) was contained (that is, it contained a high content of phospholipids). The median particle size of the nutritional composition of choline lecithin is 0.3 μm, which is greatly reduced.
將封入透明袋(pouch)中並且經殺菌釜殺菌之營養組成物與對照組成物，於40℃之恆溫器保管3個月，然後將其開封，評估存在於液層-氣層界面之乳油層。評估基準係○：少，△：多，×：非常多。The nutrient composition sealed in a pouch and sterilized by the autoclave was stored in a thermostat at 40 ° C for 3 months, and then opened, and the cream layer present at the liquid layer-gas layer interface was evaluated. . Evaluation criteria are: ○: less, △: more, ×: very much.
其結果如表4所示，對照組成物之乳油分離非常多，但含有卵磷脂(1)(即含有高含量磷脂醯膽鹼之卵磷脂)的營 養組成物之乳油分離少。The results are shown in Table 4. The emulsification of the control composition was very much separated, but the battalion containing lecithin (1) (ie, lecithin containing a high content of phospholipid choline) The emulsifiable concentrate of the nutrient composition is small.
受過官能試驗用之訓練的官能檢查員(10名)分別在盲測下試飲營養組成物、對照組成物，評估呈味性。評估基準係○：幾乎感覺不到油膩味(oily)；△：感覺到油膩味(oily)，但就飲食而言可忍受；×：強烈感覺到油膩味(oily)，不適宜飲食。其結果示於表5。The functional inspectors (10) who had been trained in the functional test were respectively tested on the nutritional composition and the control composition under blind test to evaluate the taste. Evaluation criteria ○: almost no oily taste was observed; △: oily taste was felt, but it was tolerable in terms of diet; ×: oily taste was strongly felt, and it was not suitable for eating. The results are shown in Table 5.
由該等結果可確認，在以如對照組成物之方式，將磷脂質中之磷脂醯膽鹼為37.5%之一般分級卵磷脂作為原料，並為了提高組成物中之膽鹼濃度而調配足夠的量之情況，組成物之粒徑中值大，且粗大的乳化物變多，乳化安定性降低。此亦可由產生許多乳油分離之情形來確認。又，與本發明之營養組成物相比，此種對照組成物之 呈味性差。From these results, it was confirmed that the phospholipid choline in the phospholipid was 37.5% of the general grade lecithin as a raw material in the form of, for example, a control composition, and sufficient for the choline concentration in the composition was adjusted. In the case of the amount, the median diameter of the composition is large, and the coarse emulsion is increased, and the emulsion stability is lowered. This can also be confirmed by the situation in which many emulsifiable concentrates are produced. Also, compared to the nutritional composition of the present invention, such a control composition Poor taste.
因此可確認，本發明之營養組成物之調製，必須調配磷脂質中之磷脂醯膽鹼含量提高之卵磷脂。Therefore, it was confirmed that the preparation of the nutritional composition of the present invention requires the formulation of lecithin having an increased phospholipid choline content in the phospholipid.
調查藉由本發明之營養組成物之後述效果，大鼠之營養狀態之改善效果、便臭之改善效果、及對肝臟疾病之抑制效果。此試驗中，製造依表6而調製成分之營養組成物A、營養組成物B，作為具有本發明的構成之動物試驗用營養組成物。又，同樣地調製對照組成物b。該等每100ml(100kcal)各組成物之蛋白質、碳水化合物、脂質等之淨含量示於表7。又，將市售營養組成物(Ensure liquid(註冊商標)(ABBOTT JAPAN股份有限公司))作為對照組成物a。The effect of improving the nutritional state of the rat, the effect of improving the odor, and the inhibitory effect on liver diseases were examined by the effects described later in the nutritional composition of the present invention. In this test, the nutritional composition A and the nutritional composition B which are prepared according to Table 6 were prepared as a nutritional composition for animal testing having the constitution of the present invention. Further, the control composition b was prepared in the same manner. The net contents of the proteins, carbohydrates, lipids, and the like per 100 ml (100 kcal) of each composition are shown in Table 7. Further, a commercially available nutritional composition (Ensure liquid (registered trademark) (ABBOTT JAPAN Co., Ltd.)) was used as the control composition a.
在對SD系大鼠投予每日必須能量之70%(60kcal/隻)之限制餵飼之下，依照一般方法預備飼育約1年。以每群10隻(共40隻)使用該高齡雄性大鼠(1年8個月大)(體重358至425g)。飼育環境：溫度23±2℃、濕度 50±10%、照明時間7點至19點、換氣15次/時，飲用水給予經過濾器之過濾水。分群係依據試驗開始前(1年8個月大)之體重為基準而進行，以各群組大致均等之方式分群。Under the limited feeding of 70% (60 kcal/head) of the necessary energy per day for SD rats, the breeding was carried out for about 1 year according to the general method. The aged male rats (1 year and 8 months old) (body weight 358 to 425 g) were used in groups of 10 (40 in total). Breeding environment: temperature 23±2°C, humidity 50±10%, lighting time 7:00 to 19:00, ventilation 15 times/hour, drinking water is given to the filtered water through the filter. The grouping was performed based on the body weight before the start of the experiment (1 year and 8 months old), and the groups were grouped in a substantially equal manner.
試驗剛開始時將本發明營養組成物或對照組成物以每日攝取量成為60kcal之方式分別限制投予，飼育2個月。又，試驗期間中，每週的星期一上午測定體重。飼育途中從第7週起3日內，設置採糞期間。進一步在試驗開始第4週及第8週(試驗最後一天)時將各群組的大鼠宰殺，進行肝臟之病理組織學評估。又，其他大鼠在第8週(試驗最後一天)時採取全血並宰殺，從所得血液採取血清。At the beginning of the test, the nutritional composition or the control composition of the present invention was separately administered in a manner such that the daily intake was 60 kcal, and the animals were bred for 2 months. Also, during the test period, the body weight was measured on Monday morning every week. During the feeding period, the manure collection period is set within 3 days from the 7th week. Further, rats of each group were slaughtered at the 4th week and the 8th week (the last day of the test) at the start of the test, and histopathological evaluation of the liver was performed. Further, other rats took whole blood and slaughtered at the 8th week (the last day of the test), and serum was taken from the obtained blood.
各群組的大鼠之體重變化的測定結果示於第1圖。又。以判定營養狀態為目的而測定血清中之白蛋白、總蛋白質濃度，並且測定更敏銳的營養指標之血清中之運鐵蛋白濃度，其結果示於第2圖(A.血清中之白蛋白濃度、B.血清中之總蛋白質濃度、C.血清中之運鐵蛋白濃度)。所有結果皆以平均值±標準偏差表示，各指標之群間比較係以分散分析之多重比較法(費雪檢定(Fisher’s test))進行。The measurement results of the body weight change of the rats in each group are shown in Fig. 1. also. The albumin and total protein concentration in the serum were determined for the purpose of determining the nutritional status, and the transferrin concentration in the serum of the more sensitive nutritional index was measured. The results are shown in Fig. 2 (A. Albumin concentration in serum) B. Total protein concentration in serum, C. Concentration of transferrin in serum). All results are expressed as mean ± standard deviation, and the comparison between groups of each index was performed by multiple comparison method of dispersion analysis (Fisher's test).
其結果，比起投予對照組成物a或對照組成物b之大鼠，投予本發明之營養組成物A或營養組成物B之大鼠，確認到良好的體重維持效果。再者，將該等營養組成物或對照組成物投予至出生後4週大的年輕大鼠(1群 10隻)，投予4週時，投予的組成物之間的體重增加未確認到顯著差異，顯示出同等效果。As a result, the rats in which the nutritional composition A or the nutritional composition B of the present invention was administered were compared with the rats to which the control composition a or the control composition b was administered, and a good weight maintenance effect was confirmed. Furthermore, the nutritional composition or the control composition is administered to a young rat 4 weeks after birth (1 group) 10), when the dose was administered for 4 weeks, no significant difference was observed in the weight gain between the administered compositions, showing the same effect.
又，比起投予對照組成物a或對照組成物b之大鼠，投予營養組成物A或營養組成物B之大鼠，血清中之白蛋白濃度、總蛋白質濃度、運鐵蛋白濃度亦顯著較高。Further, compared with the rats to which the control composition a or the control composition b was administered, the rats in which the nutritional composition A or the nutritional composition B was administered, the albumin concentration, the total protein concentration, and the transferrin concentration in the serum were also Significantly higher.
針對所採取之各群組的糞便，由官能檢查員(20名)依照表8所示之評估基準，官能性評估各個糞便的便臭。又，藉由表8所示之評估結果，將各群組以威爾卡森檢定法(Wilcoxon's test)做比較，結果，比起投予對照組成物a或對照組成物b之群組，投予營養組成物A或營養組成物B之群組，確認到顯著(p<0.05)有便臭之改善效果。The fecal odor of each feces was evaluated by the functional inspector (20 persons) according to the evaluation criteria shown in Table 8 for the feces of each group taken. Further, by comparing the results of the evaluation shown in Table 8, each group was compared by Wilcoxon's test, and as a result, compared with the group administered with the control composition a or the control composition b, When the group of the nutritional composition A or the nutritional composition B was added, it was confirmed that the effect of improving the stool was remarkable (p < 0.05).
關於上述所得之試驗開始後第4週及第8週之大鼠的肝臟組織，係依據下述基準評估，投予本發明之營養組成物A或對照組成物b之大鼠個別的評估結果示於表9。可確認到相對於攝取對照組成物b，攝取本發明之營養組成物得到肝臟疾病之可能性較低。The liver tissues of the rats at the 4th week and the 8th week after the start of the test obtained above were evaluated based on the following criteria, and the individual evaluation results of the rats in which the nutritional composition A or the control composition b of the present invention was administered were shown. In Table 9. It was confirmed that the intake of the nutritional composition of the present invention with respect to the ingestion of the control composition b was less likely to cause liver disease.
◎：幾乎未確認到油滴◎: Almost no oil drop confirmed
○：散佈有小滴性脂肪滴○: scattered droplets of fat droplets
△：確認到大滴性脂肪滴△: Confirmation of large drops of fat
×：確認到巨大滴性脂肪滴，且確認到組織纖維化×: A large drip fat droplet was confirmed, and tissue fibrosis was confirmed.
該等實施例、試驗例之結果可確認，本發明之營養組成物不僅具有與以往的營養組成物(對照組成物a)等相等的效果，並且對營養狀態容易惡化的高齡者之營養狀態的維持性優異。又，可確認有效改善便臭、對肝臟疾病之抑制效果亦高。As a result of the above-mentioned examples and the test examples, it was confirmed that the nutritional composition of the present invention has an effect equivalent to that of the conventional nutritional composition (control composition a) and the nutritional state of an elderly person whose nutritional status is likely to deteriorate. Excellent maintainability. Further, it was confirmed that the effective improvement of the odor and the suppression of liver diseases were also high.
本發明之營養組成物藉由調配磷脂質中之 磷脂醯膽鹼含量提高之卵磷脂，而可提供作為乳化安定性高、呈味性優異者。如此之本發明之營養組成物可提供作為以需要營養的人等為攝取或投予對象之營養組成物。本發明之營養組成物，可提供作為由於可維持、改善營養狀態容易惡化、消化道功能差的高齡者等之營養狀態而尤其對高齡者等有用之營養組成物等。又，本發明之營養組成物具有有效改善便臭、對肝臟疾病之抑制效果亦高之優點。The nutritional composition of the present invention is prepared by blending a phospholipid A lecithin having an increased phospholipid choline content, and which is excellent in emulsification stability and excellent in taste. The nutritional composition of the present invention can be provided as a nutritional composition for ingesting or administering a subject such as a person in need of nutrition. In the nutritional composition of the present invention, it is possible to provide a nutritional composition which is useful for an elderly person or the like as a nutritional state such as an elderly person who can maintain and improve a nutritional state and which has a poor gastrointestinal function. Further, the nutritional composition of the present invention has an advantage of effectively improving the odor and suppressing the liver disease.
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW102109178A TWI450692B (en) | 2013-03-15 | 2013-03-15 | Nutrient composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW102109178A TWI450692B (en) | 2013-03-15 | 2013-03-15 | Nutrient composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201340887A TW201340887A (en) | 2013-10-16 |
| TWI450692B true TWI450692B (en) | 2014-09-01 |
Family
ID=49771176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW102109178A TWI450692B (en) | 2013-03-15 | 2013-03-15 | Nutrient composition |
Country Status (1)
| Country | Link |
|---|---|
| TW (1) | TWI450692B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003313142A (en) * | 2002-02-20 | 2003-11-06 | En Otsuka Pharmaceutical Co Ltd | Nutrition composition |
| CN102164595A (en) * | 2008-09-19 | 2011-08-24 | 雀巢产品技术援助有限公司 | Nutritional support of the immune system during anti-cancer treatment |
-
2013
- 2013-03-15 TW TW102109178A patent/TWI450692B/en not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003313142A (en) * | 2002-02-20 | 2003-11-06 | En Otsuka Pharmaceutical Co Ltd | Nutrition composition |
| CN102164595A (en) * | 2008-09-19 | 2011-08-24 | 雀巢产品技术援助有限公司 | Nutritional support of the immune system during anti-cancer treatment |
Also Published As
| Publication number | Publication date |
|---|---|
| TW201340887A (en) | 2013-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI332399B (en) | Nutritional composition for controlling blood sugar level | |
| US20230270151A1 (en) | Nutritional composition having lipophilic compounds with improved solubility and bioavailability | |
| JP5574561B2 (en) | Total enteral nutrition composition | |
| JP6609555B2 (en) | Brain function improving agent and preventive or therapeutic agent for cognitive impairment | |
| US11606966B2 (en) | Nutritional formula | |
| CN105263505A (en) | Compositions for use in cartilage breakdown | |
| CN104853621A (en) | Nutritional formulations using human milk oligosaccharides for modulating inflammation | |
| CA2821312A1 (en) | Methods for facilitating muscle recovery after a period of disuse using beta-hydroxy-beta-methylbutyrate | |
| TW201039759A (en) | Reduction of risk of obesity | |
| TW201236578A (en) | Nutritional products comprising beta-hydroxy-beta-methylbutyrate | |
| CN105246499A (en) | Compositions for use in cartilage breakdown | |
| CN107106653A (en) | Alimentation composition available for treatment IBD patient | |
| EP0391218B1 (en) | Agent for the atopy prophylaxis | |
| IL228528A (en) | Potato protein nanoparticles | |
| JP2003313142A (en) | Nutrition composition | |
| CN101631542A (en) | Nerve regeneration agent | |
| TWI450692B (en) | Nutrient composition | |
| CN109153693B (en) | Safe and stable plasmalogen, preparation thereof, and method for determining non-diseased state of cognitive disorder | |
| JP5735576B2 (en) | Composition containing coenzyme Q10 | |
| JP2000302677A (en) | Medicine and food/feed composition having improving action on carnitine self production ability | |
| NZ716779B2 (en) | Nutritional composition having lipophilic compounds with improved solubility and bioavailability | |
| JP2005154401A (en) | Deodorizing composition for feces | |
| TW201233341A (en) | Nutritional products comprising calcium beta-hydroxy-beta methylbutyrate and conjugated linoleic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |